Key facts
- VuEssence’s last known valuation is $21.0M (Jan 2020).
- It has raised $3.8M across 3 recorded rounds; the latest was Seed Round ($1.1M) in Dec 2019.
- Notable investors include Embarc Collective, Tampa Bay Technology Incubator.
- VuEssence has filed 4 Form Ds with the SEC since 2016, most recently May 2025 ($48K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for VuEssence
Funding rounds
3 roundsAbout VuEssence
Developer of a biotechnology research platform intended to help detect and manage stroke. The company's platform develops practical solutions that decipher the human genome and transcription, enabling physicians to get assistance in managing patients with serious conditions.
- Sector
- Healthcare
- HQ
- Odessa, FL, United States
- Founded
- 2010
- Employees
- 5
- Website
- vuessence.com/
- Ownership
- Privately Held (backing)
VuEssence doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VuEssence shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VuEssence in its N-PORT filings yet. We sweep new filings monthly.